Recro Reports Inducement Grants for New Staff
MALVERN, PA — Recro Pharma, Inc. (NASDAQ: REPH) this week announced the expansion of its team through the addition of new employees primarily in the areas of analytical development, business …
Read MoreRecro Pharma
Recro (Nasdaq: REPH), headquartered in Malvern, PA, is a contract development and manufacturing organization, or CDMO, with integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. For more information see www.recrocdmo.com.
Recro Works to Expand and Diversify Customer Base
MALVERN, PA — Recro Pharma, Inc. (NASDAQ: REPH) announced significant recent progress in strengthening the company’s business development team to support its strategic objective of expanding and diversifying its customer …
Read More Recro to Present at H.C. Wainwright Global Life Science Conference
MALVERN, PA — Recro Pharma, Inc. (NASDAQ: REPH) announced that its chief executive officer, David Enloe, will deliver a corporate presentation as part of the H.C. Wainwright Global Life Science …
Read More Recro Reports Fourth Quarter and Year End 2020 Financial Results
MALVERN, PA — Recro Pharma, Inc. (NASDAQ: REPH), a dedicated contract development and manufacturing organization (CDMO), solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, …
Read More Recro Announces Amendment to Athyrium Credit Facility
MALVERN, PA — Recro Pharma, Inc. (NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug …
Read More Recro to Report Financial Results for Fourth Quarter And Year-End 2020
MALVERN, PA — Recro Pharma, Inc. (NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug …
Read More Recro Strengthens Leadership Team With Key Executive and Board Appointments
MALVERN, PA — Recro Pharma, Inc. (NASDAQ: REPH), a dedicated contract development and manufacturing organization (CDMO) solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, …
Read More Recro Grants Inducement Award to New Chief Executive Officer
MALVERN, PA — Recro (Nasdaq: REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and …
Read More Recro Announces Executive Changes
MALVERN, PA — Recro (Nasdaq: REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and …
Read More Recro Reports Third Quarter 2020 Financial Results
MALVERN, PA — Recro (Nasdaq: REPH) has reported financial results for the three and nine months ended September 30, 2020.
Read More